In 2022, The National Center for Comprehensive Assessment of Drug and Health Technology, in collaboration with relevant units, developed three technical guidelines for clinical comprehensive evaluation (for trial) of cardiovascular diseases, pediatric drugs and antineoplastic drugs, respectively. All guidelines mention that multi-criteria decision analysis (MCDA) can be used to rank the comprehensive value of drugs and help decision makers to make tradeoffs among multiple criteria to determine the best choice. At the same time, the guidelines mention, but do not go into depth, the weighting techniques that may be used in the MCDA process. This paper briefly composed the operational steps and characteristics of weighting techniques mentioned in the guidelines, hoping to promote the application of MCDA in the process of drugs clinical comprehensive evaluation in China and to form a MCDA method suitable for China's national conditions.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |